Vantrexa · SCLC · France · Oncology pharmacist · captured by Mei Tanaka on 11 Aug 2026 · reviewed by Dr. Elena Moretti on 15 Aug 2026
Verbatim as captured; never edited
Oncology pharmacist at Gustave Roussy raised pd-l1 testing turnaround during a congress meeting. They requested supporting literature and a follow-up discussion.
Human-approved by Dr. Elena Moretti on 15 Aug 2026
PD-L1 testing turnaround: request for data reported by oncology pharmacist (FR).
No AI assistance
Transparent weighted model; contribution = value ÷ 5 × weight
| Dimension | Value (1–5) | Weight | Contribution |
|---|---|---|---|
| Patient relevance | 4 | 20% | 16.0 |
| Strategic alignment | 5 | 20% | 20.0 |
| Scientific importance | 3 | 15% | 9.0 |
| Urgency | 4 | 15% | 12.0 |
| Novelty | 4 | 10% | 8.0 |
| Actionability | 2 | 10% | 4.0 |
| Confidence | 2 | 5% | 2.0 |
| Breadth of occurrence | 2 | 5% | 2.0 |
| Total | High 73 | ||
No audit events in sample data
Every model call on this record and its human outcome
No AI interactions in sample data
Current stage and the next allowed action
Who reviewed, what action, which function, what decision, what outcome, when closed
09 Aug 2026 · Dr. Chloé Xu, Gustave Roussy · MSL Mei Tanaka
Insight
Reviewed 15 Aug 2026 by Dr. Elena Moretti
Action
Publication project · David Chen · In progress
Decision
Outcome
Closure